15.286 articles found

LRRK2 Inhibitors as Promising Treatment for Parkinson's Disease.

Tan S, Liu H, Yao X.

ACS Chem Neurosci · 2024-11-02

DOI: 10.1021/acschemneuro.4c00657PMID: 39487783

Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses.

Mantovani E, Martini A, Dinoto A, Zucchella C, Ferrari S, Mariotto S, Tinazzi M, Tamburin S.

NPJ Parkinsons Dis · 2024-11-02

DOI: 10.1038/s41531-024-00823-xPMID: 39488513

Erythrocytic α-Synuclein in Parkinson's Disease and Progressive Supranuclear Palsy-A Pilot Study.

Cristiani CM, Scaramuzzino L, Parrotta EI, Cuda G, Quattrone A, Quattrone A.

Biomedicines · 2024-11-02

DOI: 10.3390/biomedicines12112510PMID: 39595076

TMEM16F regulates pathologic α-synuclein secretion and spread in cellular and mouse models of Parkinson's disease.

Cohen-Adiv S, Amer-Sarsour F, Berdichevsky Y, Boxer E, Goldstein O, Gana-Weisz M, Tripathi U, Rike WA, Prag G, Gurevich T, Giladi N, Stern S, Orr-Urtreger A, Friedmann-Morvinski D, Ashkenazi A.

Aging Cell · 2024-11-02

DOI: 10.1111/acel.14387PMID: 39487963

Human iPSC-derived pericyte-like cells carrying the LRRK2 mutation induce a reactive phenotype and alter migration

Peltonen S, Sonninen T, Niskanen J, Koistinaho J, Ruponen M, Lehtonen Š.

· 2024-11-01

DOI: 10.21203/rs.3.rs-5104876/v1

Nanotherapeutic Approaches of Interleukin‐3 to Clear the α‐Synuclein Pathology in Mouse Models of Parkinson's Disease (Adv. Sci. 42/2024)

Check source for author details

Advanced Science · 2024-11-01

Microglia: roles and genetic risk in Parkinson's disease.

Trainor AR, MacDonald DS, Penney J.

Front Neurosci · 2024-11-01

DOI: 10.3389/fnins.2024.1506358PMID: 39554849

Distinct ultrastructural phenotypes of glial and neuronal alpha-synuclein inclusions in multiple system atrophy.

Böing C, Di Fabrizio M, Burger D, Bol JGJM, Huisman E, Rozemuller AJM, van de Berg WDJ, Stahlberg H, Lewis AJ.

Brain · 2024-11-01

DOI: 10.1093/brain/awae137PMID: 38696728

14-3-3 phosphorylation inhibits 14-3-3θ's ability to regulate LRRK2 kinase activity and toxicity.

Pattanayak R, Ekkatine R, Petit CM, Yacoubian TA.

Hum Mol Genet · 2024-11-01

DOI: 10.1093/hmg/ddae142PMID: 39324210

α-Synuclein in Parkinson's Disease: 12 Years Later.

Vekrellis K, Emmanouilidou E, Xilouri M, Stefanis L.

Cold Spring Harb Perspect Med · 2024-11-01

DOI: 10.1101/cshperspect.a041645PMID: 39349314

Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases.

Sokratian A, Zhou Y, Tatli M, Burbidge KJ, Xu E, Viverette E, Donzelli S, Duda AM, Yuan Y, Li H, Strader S, Patel N, Shiell L, Malankhanova T, Chen O, Mazzulli JR, Perera L, Stahlberg H, Borgnia M, Bartesaghi A, Lashuel HA, West AB.

Sci Adv · 2024-11-01

DOI: 10.1126/sciadv.adq3539PMID: 39485845

AVE0991 ameliorates dopaminergic neuronal damage in Parkinson's disease through HOTAIRM1/miR-223-3p/α-synuclein axis.

Duan R, Shi L, Deng Y, Wu J, Wang S, Peng Q, Li Z, Xu Z, Wang F, Xue X, Gao Q.

Sci Rep · 2024-11-01

DOI: 10.1038/s41598-024-76058-wPMID: 39487232